MedTrace Logo

Treatment of Recurrent/Metastatic Head and Neck Cancer

NCT07601204 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2026-05-22

No results posted yet for this study

Summary

This study is a Phase Ib/II study of TQB2922 injection (subcutaneous). In the Phase Ib stage, a 3+3 dose-escalation design was used to determine the RP2D and pharmacokinetic characteristics of TQB2922 injection (subcutaneous) administered once every 3 weeks in subjects with R/M HNC. The Phase II stage explored the efficacy and safety of TQB2922 (subcutaneous) as monotherapy or in combination therapy in subjects with R/M HNC.

Conditions

  • Recurrent/Metastatic Head and Neck Cancer

Interventions

DRUG

TQB2922 Subcutaneous Injection

TQB2922 injection is a bispecific antibody against Epidermal Growth Factor Receptor (EGFR)/Hepatocyte Growth Factor Receptor (c-Met).

Sponsors & Collaborators

  • Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-02-28
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07601204 on ClinicalTrials.gov